Langbahn Team – Weltmeisterschaft

CHEK1

CHEK1
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesCHEK1, CHK1, checkpoint kinase 1
External IDsOMIM: 603078; MGI: 1202065; HomoloGene: 975; GeneCards: CHEK1; OMA:CHEK1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

1111

12649

Ensembl

ENSG00000149554

ENSMUSG00000032113

UniProt

O14757

O35280

RefSeq (mRNA)

NM_007691

RefSeq (protein)

NP_031717

Location (UCSC)Chr 11: 125.63 – 125.68 MbChr 9: 36.62 – 36.64 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Checkpoint kinase 1, commonly referred to as Chk1, is a serine/threonine-specific protein kinase that, in humans, is encoded by the CHEK1 gene.[5][6] Chk1 coordinates the DNA damage response (DDR) and cell cycle checkpoint response.[7] Activation of Chk1 results in the initiation of cell cycle checkpoints, cell cycle arrest, DNA repair and cell death to prevent damaged cells from progressing through the cell cycle.

Discovery

In 1993, Beach and associates initially identified Chk1 as a serine/threonine kinase which regulates the G2/M phase transition in fission yeast.[8] Constitutive expression of Chk1 in fission yeast was shown to induce cell cycle arrest. The same gene called Rad27 was identified in budding yeast by Carr and associates. In 1997, homologs were identified in more complex organisms including the fruit fly, human and mouse.[9] Through these findings, it is apparent Chk1 is highly conserved from yeast to humans.[5]

Structure

Human Chk1 is located on chromosome 11 on the cytogenic band 11q22-23. Chk1 has a N-terminal kinase domain, a linker region, a regulatory SQ/TQ domain and a C-terminal domain.[9] Chk1 contains four Ser/Gln residues.[8] Chk 1 activation occurs primarily through the phosphorylation of the conserved sites, Ser-317, Ser-345 and less often at Ser-366.[8][10]

Function

Checkpoint kinases (Chks) are protein kinases that are involved in cell cycle control. Two checkpoint kinase subtypes have been identified, Chk1 and Chk2. Chk1 is a central component of genome surveillance pathways and is a key regulator of the cell cycle and cell survival. Chk1 is required for the initiation of DNA damage checkpoints and has recently been shown to play a role in the normal (unperturbed) cell cycle.[9] Chk1 impacts various stages of the cell cycle including the S phase, G2/M transition and M phase.[8]

In addition to mediating cell cycle checkpoints, Chk1 also contributes to DNA repair processes, gene transcription, egg production, embryo development, cellular responses to HIV infection and somatic cell viability.[8][11]

S phase

Chk1 is essential for the maintenance of genomic integrity. Chk1 monitors DNA replication in unperturbed cell cycles and responds to genotoxic stress if present.[9] Chk1 recognizes DNA strand instability during replication and can stall DNA replication in order to allow time for DNA repair mechanisms to restore the genome.[8] Recently, Chk1 has shown to mediate DNA repair mechanisms and does so by activating various repair factors. Furthermore, Chk1 has been associated with three particular aspects of the S-phase, which includes the regulation of late origin firing, controlling the elongation process and maintenance of DNA replication fork stability.[8]

G2/M transition

In response to DNA damage, Chk1 is an important signal transducer for G2/M checkpoint activation. Activation of Chk1 holds the cell in the G2 phase until ready to enter the mitotic phase. This delay allows time for DNA to repair or cell death to occur if DNA damage is irreversible.[12] Chk1 must inactivate in order for the cell to transition from the G2 phase into mitosis, Chk1 expression levels are mediated by regulatory proteins.

M phase

Chk1 has a regulatory role in the spindle checkpoint however the relationship is less clear as compared to checkpoints in other cell cycle stages. During this phase the Chk1 activating element of ssDNA can not be generated suggesting an alternate form of activation. Studies on Chk1 deficient chicken lymphoma cells have shown increased levels of genomic instability and failure to arrest during the spindle checkpoint phase in mitosis.[8] Furthermore, haploinsufficient mammary epithelial cells illustrated misaligned chromosomes and abnormal segregation. These studies suggest Chk1 depletion can lead to defects in the spindle checkpoint resulting in mitotic abnormalities.

Interactions

DNA damage induces the activation of Chk1 which facilitates the initiation of the DNA damage response (DDR) and cell cycle checkpoints. The DNA damage response is a network of signaling pathways that leads to activation of checkpoints, DNA repair and apoptosis to inhibit damaged cells from progressing through the cell cycle.

Chk1 activation

Chk1 is regulated by ATR through phosphorylation, forming the ATR-Chk1 pathway. This pathway recognizes single strand DNA (ssDNA) which can be a result of UV-induced damage, replication stress and inter-strand cross linking.[8][9] Often ssDNA can be a result of abnormal replication during S phase through the uncoupling of replication enzymes helicase and DNA polymerase.[8] These ssDNA structures attract ATR and eventually activates the checkpoint pathway.

However, activation of Chk1 is not solely dependent on ATR, intermediate proteins involved in DNA replication are often necessary. Regulatory proteins such as replication protein A, Claspin, Tim/Tipin, Rad 17, TopBP1 may be involved to facilitate Chk1 activation. Additional protein interactions are involved to induce maximal phosphorylation of Chk1. Chk1 activation can also be ATR-independent through interactions with other protein kinases such as PKB/AKT, MAPKAPK and p90/RSK.[8]

Also, Chk1 has been shown to be activated by the Scc1 subunit of the protein cohesin, in zygotes.[13]

Cell cycle arrest

Chk1 interacts with many downstream effectors to induce cell cycle arrest. In response to DNA damage, Chk1 primarily phosphorylates Cdc25 which results in its proteasomal degradation.[9] The degradation has an inhibitory effect on the formation of cyclin-dependent kinase complexes, which are key drivers of the cell cycle.[14] Through targeting Cdc25, cell cycle arrest can occur at multiple time points including the G1/S transition, S phase and G2/M transition.[8] Furthermore, Chk1 can target Cdc25 indirectly through phosphorylating Nek11.

WEE1 kinase and PLK1 are also targeted by Chk1 to induce cell cycle arrest. Phosphorylation of WEE1 kinase inhibits cdk1 which results in cell cycle arrest at the G2 phase.[8]

Chk1 has a role in the spindle checkpoint during mitosis thus interacts with spindle assembly proteins Aurora A kinase and Aurora B kinase.[9]

DNA repair

Recently, Chk1 has shown to mediate DNA repair mechanisms and does so by activating repair factors such as proliferating cell nuclear antigen (PCNA), FANCE, Rad51 and TLK.[8] Chk1 facilitates replication fork stabilization during DNA replication and repair however more research is necessary to define the underlying interactions.[9]

Clinical relevance

Chk1 has a central role in coordinating the DNA damage response and therefore is an area of great interest in oncology and the development of cancer therapeutics.[15] Initially Chk1 was thought to function as a tumor suppressor due to the regulatory role it serves amongst cells with DNA damage. However, there has been no evidence of homozygous loss of function mutants for Chk1 in human tumors.[8] Instead, Chk1 has been shown to be overexpressed in numerous tumors including breast, colon, liver, gastric and nasopharyngeal carcinoma.[8] There is a positive correlation with Chk1 expression and tumor grade and disease recurrence suggesting Chk1 may promote tumor growth.[8][9][15] Chk1 is essential for cell survival and through high levels of expressions in tumors the function may be inducing tumor cell proliferation. Further, a study has demonstrated that targeting Chk1 reactivates the tumour suppressive activity of protein phosphtase 2A (PP2A) complex in cancer cells.[16] Studies have shown complete loss of Chk1 suppresses chemically induce carcinogenesis however Chk1 haploinsufficiency results in tumor progression.[9] Due to the possibility of Chk1 involvement in tumor promotion, the kinase and related signaling molecules may be potentially effective therapeutic targets. Cancer therapies utilize DNA damaging therapies such as chemotherapies and ionizing radiation to inhibit tumor cell proliferation and induce cell cycle arrest.[17] Tumor cells with increased levels of Chk1 acquire survival advantages due to the ability to tolerate a higher level of DNA damage. Therefore, Chk1 may contribute to chemotherapy resistance.[18] In order to optimize chemotherapies, Chk1 must be inhibited to reduce the survival advantage.[7] Chk1 gene can be effectively silenced by siRNA knockdown for further analysis based on an independent validation.[19] By inhibiting Chk1, cancer cells lose the ability to repair damaged DNA which allows chemotherapeutic agents to work more effectively. Combining DNA damaging therapies such as chemotherapy or radiation treatment with Chk1 inhibition enhances targeted cell death and provides synthetic lethality.[20] Many cancers rely on Chk1 mediated cell cycle arrest heavily especially if cancers are deficient in p53.[21] Approximately 50% of cancers possess p53 mutations illustrating the dependence that many cancers may have on the Chk1 pathway.[22][23][24] Inhibition of Chk1 allows selective targeting of p53 mutant cells as Chk1 levels are more likely to highly expressed in tumor cells with p53 deficiencies.[15][25] Even though this method of inhibition is highly targeted, recent research has shown Chk1 also has a role in the normal cell cycle.[26] Therefore, off-target effects and toxicity associated with combination therapies using Chk1 inhibitors must be considered during development of novel therapies.[27]

In a combined computational approach, a set of in-house plant-based semi-synthetic aminoarylbenzosuberene molecules selected for analysis, from these Bch10 regarded as a potential CHK1 inhibitor compared to the top five co-crystallized inhibitors based on their binding affinity and toxicity profile.[28]

Meiosis

During meiosis in human and mouse, CHEK1 protein kinase is important for integrating DNA damage repair with cell cycle arrest.[29] CHEK1 is expressed in the testes and associates with meiotic synaptonemal complexes during the zygonema and pachynema stages.[29] CHEK1 likely acts as an integrator for ATM and ATR signals and may be involved in monitoring meiotic recombination.[29] In mouse oocytes CHEK1 appears to be indispensable for prophase I arrest and to function at the G2/M checkpoint.[30]

See also

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000149554 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000032113 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, et al. (September 1997). "Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25". Science. 277 (5331): 1497–501. doi:10.1126/science.277.5331.1497. PMID 9278511.
  6. ^ Flaggs G, Plug AW, Dunks KM, Mundt KE, Ford JC, Quiggle MR, et al. (December 1997). "Atm-dependent interactions of a mammalian chk1 homolog with meiotic chromosomes". Current Biology. 7 (12): 977–86. Bibcode:1997CBio....7..977F. doi:10.1016/S0960-9822(06)00417-9. PMID 9382850. S2CID 14734991.
  7. ^ a b McNeely S, Beckmann R, Bence Lin AK (April 2014). "CHEK again: revisiting the development of Chk1 inhibitors for cancer therapy". Pharmacology & Therapeutics. 142 (1): 1–10. doi:10.1016/j.pharmthera.2013.10.005. PMID 24140082.
  8. ^ a b c d e f g h i j k l m n o p q Zhang Y, Hunter T (March 2014). "Roles of Chk1 in cell biology and cancer therapy". International Journal of Cancer. 134 (5): 1013–23. doi:10.1002/ijc.28226. PMC 3852170. PMID 23613359.
  9. ^ a b c d e f g h i j Patil M, Pabla N, Dong Z (November 2013). "Checkpoint kinase 1 in DNA damage response and cell cycle regulation". Cellular and Molecular Life Sciences. 70 (21): 4009–21. doi:10.1007/s00018-013-1307-3. PMC 3731415. PMID 23508805.
  10. ^ Caparelli ML, O'Connell MJ (March 2013). "Regulatory motifs in Chk1". Cell Cycle. 12 (6): 916–22. doi:10.4161/cc.23881. PMC 3637350. PMID 23422000.
  11. ^ Ruth KS, Day FR, Hussain J, Martínez-Marchal A, Aiken CE, Azad A, et al. (August 2021). "Genetic insights into biological mechanisms governing human ovarian ageing". Nature. 596 (7872): 393–397. Bibcode:2021Natur.596..393R. doi:10.1038/s41586-021-03779-7. PMC 7611832. PMID 34349265.
  12. ^ Meuth M (September 2010). "Chk1 suppressed cell death". Cell Division. 5: 21. doi:10.1186/1747-1028-5-21. PMC 2939633. PMID 20813042.
  13. ^ Ladstätter S, Tachibana-Konwalski K (December 2016). "A Surveillance Mechanism Ensures Repair of DNA Lesions during Zygotic Reprogramming". Cell. 167 (7): 1774–1787.e13. doi:10.1016/j.cell.2016.11.009. PMC 5161750. PMID 27916276.
  14. ^ Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. (June 2000). "Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint". Genes & Development. 14 (12): 1448–59. doi:10.1101/gad.840500. PMC 316686. PMID 10859164.
  15. ^ a b c Goto H, Izawa I, Li P, Inagaki M (July 2012). "Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti-cancer therapy?". Cancer Science. 103 (7): 1195–200. doi:10.1111/j.1349-7006.2012.02280.x. PMC 7659239. PMID 22435685. S2CID 205237831.
  16. ^ Khanna A, Kauko O, Böckelman C, Laine A, Schreck I, Partanen JI, et al. (November 2013). "Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells". Cancer Research. 73 (22): 6757–69. doi:10.1158/0008-5472.CAN-13-1002. PMC 3870284. PMID 24072747.
  17. ^ Smith J, Tho LM, Xu N, Gillespie DA (2010). The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Vol. 108. pp. 73–112. doi:10.1016/B978-0-12-380888-2.00003-0. ISBN 978-0-12-380888-2. PMID 21034966. {{cite book}}: |journal= ignored (help)
  18. ^ Liang Y, Lin SY, Brunicardi FC, Goss J, Li K (April 2009). "DNA damage response pathways in tumor suppression and cancer treatment". World Journal of Surgery. 33 (4): 661–6. doi:10.1007/s00268-008-9840-1. PMID 19034564. S2CID 13599990.
  19. ^ Munkácsy G, Sztupinszki Z, Herman P, Bán B, Pénzváltó Z, Szarvas N, et al. (September 2016). "Validation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments". Molecular Therapy: Nucleic Acids. 5 (9): e366. doi:10.1038/mtna.2016.66. PMC 5056990. PMID 27673562.
  20. ^ Toledo LI, Murga M, Fernandez-Capetillo O (August 2011). "Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs". Molecular Oncology. 5 (4): 368–73. doi:10.1016/j.molonc.2011.07.002. PMC 3590794. PMID 21820372.
  21. ^ Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, Kovar P, et al. (December 2006). "Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics". International Journal of Cancer. 119 (12): 2784–94. doi:10.1002/ijc.22198. PMID 17019715. S2CID 22922827.
  22. ^ Maugeri-Saccà M, Bartucci M, De Maria R (August 2013). "Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy". Cancer Treatment Reviews. 39 (5): 525–33. doi:10.1016/j.ctrv.2012.10.007. PMID 23207059.
  23. ^ Tao ZF, Lin NH (July 2006). "Chk1 inhibitors for novel cancer treatment". Anti-Cancer Agents in Medicinal Chemistry. 6 (4): 377–88. doi:10.2174/187152006777698132. PMID 16842237.
  24. ^ Ma CX, Janetka JW, Piwnica-Worms H (February 2011). "Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics". Trends in Molecular Medicine. 17 (2): 88–96. doi:10.1016/j.molmed.2010.10.009. PMC 6905465. PMID 21087899.
  25. ^ Zenvirt S, Kravchenko-Balasha N, Levitzki A (November 2010). "Status of p53 in human cancer cells does not predict efficacy of Chk1 kinase inhibitors combined with chemotherapeutic agents". Oncogene. 29 (46): 6149–59. doi:10.1038/onc.2010.343. PMID 20729914.
  26. ^ Thompson R, Eastman A (September 2013). "The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design". British Journal of Clinical Pharmacology. 76 (3): 358–69. doi:10.1111/bcp.12139. PMC 3769664. PMID 23593991.
  27. ^ Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S (April 2011). "CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle". Molecular Interventions. 11 (2): 133–40. doi:10.1124/mi.11.2.11. PMC 3109860. PMID 21540473.
  28. ^ Singh R, Bhardwaj VK, Sharma J, Das P, Purohit R (January 2021). "Discovery and in silico evaluation of aminoarylbenzosuberene molecules as novel checkpoint kinase 1 inhibitor determinants". Genomics. 113 (1): 707–715. doi:10.1016/j.ygeno.2020.10.001. PMID 33065246. S2CID 223556335.
  29. ^ a b c Flaggs G, Plug AW, Dunks KM, Mundt KE, Ford JC, Quiggle MR, et al. (December 1997). "Atm-dependent interactions of a mammalian chk1 homolog with meiotic chromosomes". Current Biology. 7 (12): 977–86. Bibcode:1997CBio....7..977F. doi:10.1016/s0960-9822(06)00417-9. PMID 9382850. S2CID 14734991.
  30. ^ Chen L, Chao SB, Wang ZB, Qi ST, Zhu XL, Yang SW, et al. (May 2012). "Checkpoint kinase 1 is essential for meiotic cell cycle regulation in mouse oocytes". Cell Cycle. 11 (10): 1948–55. doi:10.4161/cc.20279. PMID 22544319.

Further reading

Quelle: http://en.wikipedia.org/wiki/CHEK1